Shattuck Labs stock price target maintained at $18 by Raymond James

Raymond James maintained its Strong Buy rating and $18 price target on Shattuck Labs, versus a recent share price of $4.47; the stock is up 152% over the past year but down nearly 10% in the past week. Shattuck reported Q3 2026 results, has more cash than debt, and expects the RECEPTIVE-CD1 Crohn’s disease study’s topline readout in H1 2028; its HS study is planned to start in Q4 2026, with initial Phase 1 data for SL-846 expected in 2027. Analyst views vary: Needham raised its target to $19, UBS set $17, and H.C. Wainwright cut its target to $14 while maintaining Buy ratings.

Analysis

The key issue is whether Shattuck can convert a differentiated target into clinically meaningful benefit—not whether analyst price targets imply upside. A larger, three-dose Crohn’s study may improve dose-response interpretation, but also adds execution burden and potentially more cash use; verify whether enrollment and the first-half-2028 readout remain on schedule. Cash exceeding debt does not establish runway: quarterly burn and funding needs are the balance-sheet variables that matter for a development-stage company.

Near term (days to 1–3 months), analyst endorsements are weak catalysts absent new clinical or financing information. Watch for confirmation that the hidradenitis study starts on schedule, trial enrollment updates, and cash-burn/runway disclosure. Over 6–18 months, human data for SL-846 and execution of SL-325 trials could change the risk profile, but the pivotal Crohn’s readout remains distant. Any eventual efficacy signal must compete with established inflammatory-disease therapies, including products from AbbVie and Novartis; target novelty alone does not establish commercial differentiation.

Contrarian view: the bullish case may underweight duration and dilution risk, while the recent pullback may also overstate what has changed if trial timelines and funding remain intact. The 2028 readout leaves substantial time for sentiment to move on interim execution rather than fundamentals.

Key Decisions for Investors

• No catalyst-driven trade on analyst targets alone. Keep STTK on a clinical-execution watchlist and verify quarterly cash burn, stated runway, trial enrollment, and whether the Crohn’s readout timing is unchanged.
• For investors with biotech risk capacity, consider only a small, risk-budgeted STTK position ahead of nearer execution milestones; do not size it as though the 2028 Crohn’s outcome were already de-risked. Avoid adding solely on a price-target gap.
• Reassess the thesis if the HS study start slips, enrollment or readout timing deteriorates, cash runway shortens materially, or management signals a financing need; these would strengthen the dilution and execution-risk case.
• A durable, clinically meaningful SL-325 efficacy and tolerability signal would falsify the cautious view and justify reassessing competitive differentiation. Preclinical SL-846 results or analyst reiterations alone would not.